Efficacy of Qishen Yiqi Drop Pill for Chronic Heart Failure: An Updated Meta-Analysis of 85 Studies

Table 1

Summarized results of the meta-analysis in high-quality studies.

Parameters	Category	Studies	Participants	SMD (95% CI)		(%)	Heterogeneity,
6MWD	Overall	11	1065	2.38 (1.63 to 3.13)	<0.001	96	<0.001
	Adjustment by treatment course
	1-4 wk	1	180	3.94 (3.43 to 4.44)	<0.001	NA	NA
	5-8 wk	5	475	2.13 (1.19 to 3.07)	<0.001	94	<0.001
	<8 wk	5	410	2.31 (1.10 to 3.52)	<0.001	96	<0.001
BNP	Overall	13	1464	-2.90 (-3.76 to -2.03)	<0.001	97	<0.001
	Adjustment by treatment course
	1-4 wk	2	278	-2.80 (-5.95 to 0.36)	0.08	99	<0.001
	5-8 wk	6	680	-2.70 (-3.77 to -1.63)	<0.001	96	<0.001
	<8 wk	5	506	-3.36 (-5.25 to -1.46)	<0.001	98	<0.001
NT-pro BNP	Overall	6	645	-3.58 (-5.15 to -2.01)	<0.001	98	<0.001
	Adjustment by treatment course
	1-4 wk	1	178	-0.59 (-0.90 to -0.29)	<0.001	NA	NA
	5-8 wk	2	200	-9.87 (-27.06 to 7.32)	0.26	99	<0.001
	<8 wk	3	267	-1.80 (-3.46 to -0.14)	0.03	97	<0.001
LVEF	Overall	24	2611	1.08 (0.84 to 1.33)	<0.001	88	<0.001
	Adjustment by treatment course
	1-4 wk	4	610	0.82 (0.19 to 0.45)	0.01	93	<0.001
	5-8 wk	9	962	1.29 (0.86 to 1.71)	<0.001	89	<0.001
	<8 wk	11	1039	1.02 (0.69 to 1.36)	<0.001	84	<0.001
LVEDD	Overall	14	1665	-1.34 (-1.87 to -0.80)	<0.001	96	<0.001
	Adjustment by treatment course
	1-4 wk	2	330	-1.09 (-3.25 to 1.06)	0.32	99	<0.001
	5-8 wk	7	762	-1.58 (-2.33 to -0.83)	<0.001	95	<0.001
	<8 wk	5	573	-1.10 (-2.04 to -0.15)	0.02	96	<0.001
LVESD	Overall	13	1592	-0.60 (-1.14 to -0.05)	0.03	96	<0.001
	Adjustment by treatment course
	1-4 wk	2	330	-0.67 (-1.99 to 0.65)	0.32	97	<0.001
	5-8 wk	7	762	-0.28 (-1.12 to 0.55)	0.51	97	<0.001
	<8 wk	4	500	-1.12 (-2.04 to-0.19)	0.02	95	<0.001

6MWD: 6-minute walking distance; BNP: brain natriuretic peptide; NT-pro BNP: N-terminal prohormone of BNP; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-diastolic dimensions; LVESD: left ventricular end-systolic dimensions.